Short Interest in Alterity Therapeutics Limited (NASDAQ:ATHE) Rises By 12.6%

Alterity Therapeutics Limited (NASDAQ:ATHE) saw a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 167,300 shares, a growth of 12.6% from the December 15th total of 148,600 shares. Approximately 2.0% of the shares of the stock are sold short. Based on an average daily volume of 64,600 shares, the short-interest ratio is currently 2.6 days.

Alterity Therapeutics Stock Up 1.8 %

ATHE traded up $0.06 during mid-day trading on Friday, reaching $3.42. The stock had a trading volume of 18,477 shares, compared to its average volume of 77,006. Alterity Therapeutics has a 52 week low of $1.00 and a 52 week high of $4.71. The firm’s fifty day simple moving average is $2.30 and its two-hundred day simple moving average is $1.72.

Hedge Funds Weigh In On Alterity Therapeutics

A hedge fund recently raised its stake in Alterity Therapeutics stock. HB Wealth Management LLC lifted its holdings in shares of Alterity Therapeutics Limited (NASDAQ:ATHE) by 34.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,883 shares of the company’s stock after buying an additional 8,100 shares during the quarter. HB Wealth Management LLC owned about 0.44% of Alterity Therapeutics worth $110,000 at the end of the most recent quarter. Institutional investors and hedge funds own 2.14% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Maxim Group began coverage on shares of Alterity Therapeutics in a research note on Thursday, December 12th. They issued a “buy” rating and a $8.00 target price for the company.

Alterity Therapeutics Company Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.